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Contrast Nephropathy: Isosmolar
and Low-Osmolar Contrast Media
We read with interest the meta-analysis by McCullough et al. (1)
regarding the lower incidence of contrast-induced nephropathy
(CIN) in patients who received isosmolar contrast medium
(IOCM) iodixanol, as compared with those who received low-
osmolar contrast media (LOCM). Nevertheless, we believe the
study presents some important methodological limitations that
could reduce its value.
In the meta-analysis, the greater part of the patients (789 of
1,345) included in the group receiving LOCM were given an ionic
contrast medium (CM), and only 69 patients received iopamidol,
the contrast agent that, according to recent data, seems to be the
safest of the LOCM (2,3). Therefore, the results of the meta-
analysis could derive from the small number of patients receiving
iopamidol in the LOCM group, rather than to the renal safety of
isosmolar iodixanol. Moreover, apart from the small meta-analysis
by Clauss et al. (4) comparing the nephrotoxicity of the IOCM
iotrolan with different types of LOCM (iopamidol, iopromide, and
iohexol), the previous major comparative studies supporting the
possible safety of IOCM have been performed only between
iodixanol and the monomer iohexol (5–7), which is found to be
one of the CMs most responsible for CIN (2,3). Thus, at present,
we do not perceive any definitive evidence of the presumed
advantage derived from the use of IOCM in comparison with all
of the LOCM (8).
In addition, the investigators themselves note that only 18.3% of
patients included in the meta-analysis had their final creatinine
(Cr) values measured on day 3 or later (1), whereas CIN is defined
as an increase of serum Cr levels of 0.5 mg/dl (or 44 mol/l) or a
25% or greater relative increase from baseline 48 to 72 h after a
diagnostic or interventional procedure requiring CM administra-
tion (9). We would like to understand how the researchers
completed Table 4 in their study summarizing the incidence of
CIN occurring within 72 h if only 18.3% of patients have their Cr
values recorded on day 3.
Finally, as underscored by the investigators (1), another impor-
tant bias could be identified in the lack of data relative to the
amount or type of intravenous hydration prophylactic protocol
given before and after CM administration, which could influence
the outcomes of each trial (10).
We believe that prospective, double-blind, randomized, con-
trolled trials comparing iodixanol with all LOCM would be
necessary to confirm the results of this meta-analysis.
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Reply
Dr. Detrenis and colleagues point out that only 69 patients in the
low-osmolar contrast media (LOCM) group received iopamidol
and suggest it may be a special case among LOCM agents. As a
LOCM, iopamidol has an osmolality of 796 mOsm/kg H2O
(Isovue, Bracco Diagnostics, Princeton, New Jersey; 370 mg
iodine/ml, viscosity at 37°C, 9.4 Cp), which is very similar to
iohexol (844 mOsm/kg H2O, Omnipaque, Amersham Health,
Princeton, New Jersey; 350 mg iodine/ml, viscosity at 37°C, 10.4
Cp) (1,2). Both of these agents are nonionic monomers. By
contrast, iodixanol, an iso-osmolar contrast medium (IOCM), is a
nonionic dimer with an osmolality of 290 mOsm/kg H2O (Visi-
paque, Amersham Health, 320 mg iodine/ml, viscosity at 37°C,
11.6 Cp) and when compared to the nonionic LOCM monomers
in our study had a significantly lower rise in serum creatinine (Cr)
after contrast exposure (p  0.001) (3,4). Although iopamidol and
iohexol are nearly identical in their physiochemical properties as
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LOCM agents, we agree with Dr. Detrenis and colleagues that a
large randomized trial of high-risk patients undergoing intra-
arterial contrast exposure comparing iodixanol versus iopamidol
would help further support the superior renal safety of IOCM
compared to nonionic LOCM monomers (iohexol, iopamidol,
iopromide). Such trials in lower-risk patients (5% contrast-
induced nephropathy [CIN] rate) are unlikely to show any differ-
ence between the 2 classes of agents and will not be helpful in
settling this issue.
We acknowledge that we did not have complete Cr data
through the entire time range of CIN, as many of these trials were
not designed with CIN as an end point. When available, we used
the day-3 Cr data; however, prior studies indicate the majority of
serious CIN cases have a rise in Cr 0.5 mg/dl by 24 h (5). This
source of incomplete ascertainment bias almost certainly biased our
findings to the null hypothesis (i.e., yielding fewer CIN end
points), thus strengthening our conclusions with respect to the
renal safety of iodixanol. Furthermore, because many of these were
not CIN trials, there was no control over hydration given before or
after contrast exposure. This source of variation again would work
toward biasing our results to the null hypothesis (i.e., higher-risk
patients getting more aggressive hydration). Thus, iodixanol may
in truth be associated with an even greater margin of renal safety
than demonstrated in our analysis.
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